Sarepta Therapeutics announces top-line results for part 1 of study 102 evaluating SRP-9001, its investigational gene therapy for the treatment of Duchenne muscular dystrophy (DMD) Jan. 7, 2021, >Original […]
Pfizer doses the first participant in phase 3 study for Duchenne muscular dystrophy (DMD) investigational gene therapy. January 07, 2021, > Original press release < Pfizer Inc. announced that the […]
Sarepta Therapeutics announces positive clinical results from MOMENTUM, a phase 2 clinical trial of SRP-5051 in patients with Duchenne muscular dystrophy amenable to skipping exon 51. Original press release > […]
Giving Tuesday – the global day of giving Join us for the 8th annual Giving Tuesday on December 1rst, 2020! GivingTuesday is a global day of giving that happens each […]
Catabasis Pharmaceuticals announces top-line results for the phase 3 PolarisDMD trial of edasalonexent in Duchenne muscular dystrophy. PolarisDMD Trial Did Not Achieve Primary or Secondary Endpoints – The development […]
Santhera to discontinue Phase 3 SIDEROS study and development of Puldysa® in Duchenne Muscular Dystrophy (DMD) and focus on vamorolone. Original Press Release > Pratteln, Switzerland, October 6, 2020 Santhera […]
Pfizer receives FDA fast track designation for Duchenne muscular dystrophy (DMD) investigational gene therapy. Official press release > NEW YORK–(BUSINESS WIRE) Pfizer Inc. announced that its investigational gene therapy candidate […]
Sarepta Therapeutics reports sustained functional improvement two years after treatment with SRP-9001, its investigational micro-dystrophin gene therapy for Duchenne muscular dystrophy. Results demonstrate continued safety and tolerability of SRP-9001 in four participants with Duchenne. All […]
La Force is happy to share the latest edition of the Catabasis Connection newsletter – Communicating clinical trial results. Catabasis understands the importance of clearly communicating clinical trial results with the […]
Santhera exercises option to obtain worldwide rights of Vamorolone for Duchenne muscular dystrophy (DMD) and All Other Indications La Force is happy to share this press release provided by Santhera Pharmaceuticals > […]
